CVRx enters the back half of fiscal 2026 at a delicate inflection: a commercial-stage medical device company whose single approved therapy is gaining both regulatory tailwinds and commercial headwinds simultaneously. Barostim remains the only FDA-approved neuromodulation device for heart failure with reduced ejection fraction. Reimbursement is moving in the right direction, with a new Humana Medicare Advantage policy and a proposed CMS outpatient rate that would lock in stable hospital economics for 2027. The operating story has not yet caught up to that clinical-and-reimbursement story. Second-quarter revenue of $15.7M grew 16% year-over-year. Management has now guided to slower growth in the second half, however, because sales-force productivity has lagged and one large payer is still resisting prior-authorization approvals.
The thesis here rests on three drivers compounding rather than competing. First, the BENEFIT-HF trial is enrolling patients across a substantially expanded population, opening the door to a far larger label and reimbursement envelope over the medium term. Second, the second-half commercial reset, including a Chief Revenue Officer transition announced in August, is intended to repair field execution before the broader label drives volume. Third, gross margin is already expanding, reaching 87% in the quarter from 84% a year earlier, and the operating loss is narrowing as fixed-cost leverage finally shows up in the P&L. The combination of a clinical catalyst and a commercial repair is what differentiates the next eighteen months from the prior eighteen.
A bear scenario still fits the facts. Active implanting centers grew only modestly over the prior year. Operating cash burn of $21.0M in the first half of 2026 leaves the balance sheet stretched relative to the runway required to reach profitability. The market is pricing in a real possibility that the second-half slowdown extends into fiscal 2027. CVRx remains an option on reimbursement breadth, payer behavior, and the eventual outcome of BENEFIT-HF rather than a scaled, profitable franchise today.